These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 28932579)
1. Patient reported outcomes following video assisted thoracoscopic (VATS) resection or stereotactic ablative body radiotherapy (SABR) for treatment of non-small cell lung cancer: protocol for an observational pilot study (LiLAC). Pompili C; Franks KN; Brunelli A; Hussain YS; Holch P; Callister ME; Robson JM; Papagiannopoulos K; Velikova G J Thorac Dis; 2017 Aug; 9(8):2703-2713. PubMed ID: 28932579 [TBL] [Abstract][Full Text] [Related]
2. Quality of life after VATS lung resection and SABR for early-stage non-small cell lung cancer: A longitudinal study. Pompili C; Rogers Z; Absolom K; Holch P; Clayton B; Callister M; Robson J; Brunelli A; Franks K; Velikova G Lung Cancer; 2021 Dec; 162():71-78. PubMed ID: 34741885 [TBL] [Abstract][Full Text] [Related]
3. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Chang JY; Mehran RJ; Feng L; Verma V; Liao Z; Welsh JW; Lin SH; O'Reilly MS; Jeter MD; Balter PA; McRae SE; Berry D; Heymach JV; Roth JA; Lancet Oncol; 2021 Oct; 22(10):1448-1457. PubMed ID: 34529930 [TBL] [Abstract][Full Text] [Related]
4. Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Verstegen NE; Oosterhuis JW; Palma DA; Rodrigues G; Lagerwaard FJ; van der Elst A; Mollema R; van Tets WF; Warner A; Joosten JJ; Amir MI; Haasbeek CJ; Smit EF; Slotman BJ; Senan S Ann Oncol; 2013 Jun; 24(6):1543-8. PubMed ID: 23425947 [TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
6. Patients' confidence in treatment decisions for early stage non-small cell lung cancer (NSCLC). Pompili C; Holch P; Rogers Z; Absolom K; Clayton B; Franks K; Bekker H; Velikova G Health Qual Life Outcomes; 2020 Jul; 18(1):237. PubMed ID: 32682425 [TBL] [Abstract][Full Text] [Related]
7. The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection. Snee MP; McParland L; Collinson F; Lowe CM; Striha A; Baldwin DR; Naidu B; Sebag-Montefiore D; Gregory WM; Bestall J; Hewison J; Hinsley S; Franks K Pilot Feasibility Stud; 2016; 2():5. PubMed ID: 27965826 [TBL] [Abstract][Full Text] [Related]
8. Are quality of life outcomes comparable following stereotactic radiotherapy and minimally invasive surgery for stage I lung cancer patients? Pompili C; Absolom K; Franks K; Velikova G J Thorac Dis; 2018 Dec; 10(12):7055-7063. PubMed ID: 30746252 [TBL] [Abstract][Full Text] [Related]
9. Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis. Paul S; Lee PC; Mao J; Isaacs AJ; Sedrakyan A BMJ; 2016 Jul; 354():i3570. PubMed ID: 27400862 [TBL] [Abstract][Full Text] [Related]
10. Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. Conibear J; Chia B; Ngai Y; Bates AT; Counsell N; Patel R; Eaton D; Faivre-Finn C; Fenwick J; Forster M; Hanna GG; Harden S; Mayles P; Moinuddin S; Landau D BMJ Open; 2018 Apr; 8(4):e020690. PubMed ID: 29666135 [TBL] [Abstract][Full Text] [Related]
11. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer. Phillips I; Sandhu S; Lüchtenborg M; Harden S Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):681-687. PubMed ID: 31377081 [TBL] [Abstract][Full Text] [Related]
12. Post-treatment survival difference between lobectomy and stereotactic ablative radiotherapy in stage I non-small cell lung cancer in England. Khakwani A; Harden S; Beckett P; Baldwin D; Navani N; West D; Hubbard R Thorax; 2020 Mar; 75(3):237-243. PubMed ID: 31879316 [TBL] [Abstract][Full Text] [Related]
13. Stereotactic Radiation Therapy in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Nonrandomized Clinical Trial. Palma DA; Bahig H; Hope A; Harrow S; Debenham BJ; Louie AV; Vu TTTT; Filion E; Bezjak A; Campeau MP; Duimering A; Giuliani ME; Laba JM; Lang P; Lok BH; Qu XM; Raman S; Rodrigues GB; Goodman CD; Gaede S; Morisset J; Warner A; Dhaliwal I; Ryerson CJ JAMA Oncol; 2024 May; 10(5):575-582. PubMed ID: 38451491 [TBL] [Abstract][Full Text] [Related]
14. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B; Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291 [TBL] [Abstract][Full Text] [Related]
15. Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small-cell lung cancer? Mahmood S; Bilal H; Faivre-Finn C; Shah R Interact Cardiovasc Thorac Surg; 2013 Nov; 17(5):845-53. PubMed ID: 23900381 [TBL] [Abstract][Full Text] [Related]
16. Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC). Palma DA; Nguyen TK; Kwan K; Gaede S; Landis M; Malthaner R; Fortin D; Louie AV; Frechette E; Rodrigues GB; Yaremko B; Yu E; Dar AR; Lee TY; Gratton A; Warner A; Ward A; Inculet R Radiat Oncol; 2017 Jan; 12(1):30. PubMed ID: 28129789 [TBL] [Abstract][Full Text] [Related]
17. Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial. Palma DA; Nguyen TK; Louie AV; Malthaner R; Fortin D; Rodrigues GB; Yaremko B; Laba J; Kwan K; Gaede S; Lee T; Ward A; Warner A; Inculet R JAMA Oncol; 2019 May; 5(5):681-688. PubMed ID: 30789648 [TBL] [Abstract][Full Text] [Related]
18. Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer. Lagerwaard FJ; Aaronson NK; Gundy CM; Haasbeek CJ; Slotman BJ; Senan S J Thorac Oncol; 2012 Jul; 7(7):1148-54. PubMed ID: 22610256 [TBL] [Abstract][Full Text] [Related]
19. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial. Bendixen M; Jørgensen OD; Kronborg C; Andersen C; Licht PB Lancet Oncol; 2016 Jun; 17(6):836-844. PubMed ID: 27160473 [TBL] [Abstract][Full Text] [Related]